36 results about "Depressive symptomatology" patented technology

Objective discrimination of a disease label of a depressive symptom with respect to an active state of a brain is achieved. One means for solving the problems of the present invention is to provide a discriminating device for assisting in determination of whether a subject has a depressive symptom. The discriminating device includes a storage device for storing information for identifying a classifier generated by classifier generation processing based on a signal obtained by using a brain activity detecting apparatus to measure, in advance and time-sequentially, a signal indicating a brain activity of a plurality of predetermined regions of each brain of a plurality of participants in a resting state, the plurality of participants including healthy individuals and patients with depression. The classifier is generated so as to discriminate a disease label of a depressive symptom based on a weighted sum of a plurality of functional connectivities selected by feature selection as being relevant to the disease label of the depressive symptom through machine learning from among functional connectivities of the plurality of predetermined regions. The discriminating device further includes a processor configured to execute discriminating processing of generating a classification result for the depressive symptom of the subject by using the classifier.

The present invention differentiates objective disease labels for depression symptoms relative to brain activity states. As one means to address the problem to be addressed thereby, the present invention provides a differentiation device that is for helping to determine whether a subject has depression symptoms. The differentiation device comprises a storage device that is for storing informationthat specifies a classifier that has been generated by classifier generation processing from signals obtained by using a brain activity detection device to chronologically premeasure signals that indicate brain activity in a plurality of prescribed regions of the resting brains of each of a plurality of participants that include healthy and depressive patients. The classifier: is generated on thebasis of a weighted sum of a plurality of functional connectivities that, from among functional connectivities between the plurality of prescribed regions, have, by means of machine learning, been selected by feature selection as being related to disease labels for depression symptoms; and is generated to differentiate the disease labels for depression symptoms. The differentiation device also comprises a computing device. Using the classifier, the computing device executes differentiation processing that generates classification results for the depression symptoms of the subject.

The present application provides a method for treating treatment-resistant depression in a patient in need thereof, comprising administering to said patient a therapeutically effective amount of tianeptine, subsequent to a ketamine treatment; also provided is a method of treating suicidal ideation (SI), post-traumatic stress disorder (PTSD), mild cognitive impairment (MCI) or pre-dementia co-morbid with symptoms of depression; and further provided is maintenance therapy for depression remission.

The invention relates to an in vitro or ex vivo method for differentially diagnosing a bipolar disorder and a major depressive disorder in a human patient in a need thereof presenting depressive symptoms, comprising the following steps: providing a biological sample from said patient; determining, from said biological sample, the abundance of at least one of the following cytokines TNF-α, IFN-γ, IL-6, IL-10, IL-12p40, IL-15, IL-16, IL-17A and IL-27; and diagnosing a bipolar disorder or a major depressive disorder from the determination of the abundance of the at least one of the following cytokines TNF-α, IFN-γ, IL-6, IL-10, IL-12p40, IL-15, IL-16, IL-17A and IL-27.

Disclosed herein are natural product compositions for treating ADHD and related disorders.

The invention provides a probiotic composition and its application in the preparation of comorbid constipation and depression medicines, said composition comprising Bifidobacterium animalis subspecies U9, Lactobacillus paracasei L55, Lactobacillus rhamnosus LL23 , Bifidobacterium adolescentis BQ23 and Lactobacillus acidophilus RA15. The present invention has carried out a randomized double-blind test to perform probiotic intervention on depressed patients. A total of 63 depressed patients were recruited, 31 of whom had comorbid constipation. The results showed that after 8 weeks of intervention, the Hamilton depression (HAMD) score of the probiotic group decreased to 14.2±8.0 in the depressed group with comorbid constipation, which was significantly lower than that in the placebo group (22.9±9.9, P<0.05). There was no significant difference in HAMD scores between the population probiotic group and the placebo group. The probiotic composition of the invention can effectively alleviate the depression symptoms of depressed people with comorbid constipation.

The invention discloses application of 5, 6-didehydro-pythoncidere in preparation of an antidepressant drug. A tail suspension test and a forced swimming test are that a depression model animal is placed in a severe environment and cannot escape so as to enter an intermittent motionless despair state. The antidepressant drug can relieve the despair degree of the depression model animal, so that the motionless state can be reversed, and the depression symptom is relieved. The experimental study finds that the 5, 6-didehydro-pythoncidere can relieve the despair degree of a depression model mouse, has an antidepressant effect, and has a prospect of being developed into the antidepressant drug.

The invention provides a new application of 7-alkoxy fangchinoline derivatives or pharmaceutically acceptable salts thereof in the preparation of GSK-3β inhibitors and in the treatment and improvement of depressive symptoms. The compound 1‑8 with the structure of formula (I) has shown the effect of promoting the phosphorylation of glycogen synthesis kinase ‑3β (GSK‑3β) at the level of cells and whole animals, and then inhibiting its activity; the results of animal experiments found that compound 1‑8 May be enhanced by 5‑HT 1A Receptor and melatonin receptor function, inhibits 5‑HT 2A Receptor function, inhibit GSK‑3β activity, improve depressive symptoms such as hopelessness, loss of pleasure, anxiety and sleep disorders.

The invention discloses application of 2,3,5,4-tetrahydroxystilbene-2-O-beta-D-glucoside to preparing medicaments for treating depression, in particular to application of 2,3,5,4-tetrahydroxystilbene-2-O-beta-D-glucoside as an active ingredient to preparing medicaments for treating depression. The invention provides the application of the 2,3,5,4-tetrahydroxystilbene-2-O-beta-D-glucoside as the medicaments for treating depression, and the 2,3,5,4-tetrahydroxystilbene-2-O-beta-D-glucoside is hardly innoxious and is applied to preparing medicaments for preventing or treating various depression symptoms including endogenous depression, reactive depression, masked depression, secondary depression caused by medicaments, menopausal or post-natal depression, depression induced by traumatic braininjury or brain death and depressive neurosis and medicaments for treating diabetes and depression complications and related diseases.

The invention discloses a new application of natural killer (NK) cellular immunotherapy. An animal model is utilized to research the influence of NK cell in combination with fluoxetine for treating monoamine neurotransmitter, peripheral blood cell factor level and depression action in brain of a rat having chronic unpredictable depression; clinically, improvement of depression symptoms of a patient and adjustment of immunity index by irradiating NK-92 cell in combination with paroxetine are evaluated, and remarkable improvement on the depression symptom by an NK cell immunotherapy is proved. Therefore, the NK cell immunotherapy in combination with the antidepressant can remarkably improve the depression symptoms.